1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Gamma Therapeutics, Inc. - Product Pipeline Analysis, 2016 Update

Summary

Gamma Therapeutics, Inc. (Gamma Therapeutics) is a biotechnology company which offers biopharmaceutical and diagnostic test solutions. The company’s product portfolio encompasses GammaCoeur, Gammarin and GammaSeal. GammaCoeur is developed to address the need for a new cardiovascular disease risk assay and complement traditional testing methods such as total fibrinogen, cholesterol for heart attack and stroke risk. Gammarin, a non-immunogenic, anticoagulant is a pharmaceutical drug that is being developed for use in patients undergoing major surgery. GammaSeal, a high strength surgical sealant is being developed for areas of mechanical strain such as wound repair or large artery vascular surgery. Its products are developed based on its technology, Gamma Prime Fibrinogen, which is a natural occurring protein in human blood. Gamma Therapeutics is headquartered in Portland, Oregon, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Gamma Therapeutics, Inc.
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Table Of Contents

Gamma Therapeutics, Inc. - Product Pipeline Analysis, 2016 Update
Table of Contents
Table of Contents 2


Gamma Therapeutics, Inc. Company Snapshot 5
Gamma Therapeutics, Inc. Company Overview 5
Gamma Therapeutics, Inc. Pipeline Products and Clinical Trials Overview 6
Gamma Therapeutics, Inc. - Pipeline Analysis Overview 8
Key Facts 8
Gamma Therapeutics, Inc. - Major Products and Services 9
Gamma Therapeutics, Inc. Pipeline Products by Development Stage 10
Gamma Therapeutics, Inc. Pipeline Products Overview 11
GammaMist 11
GammaMist Product Overview 11
GammaSeal 12
GammaSeal Product Overview 12
GammaTF 13
GammaTF Product Overview 13
Gamma Therapeutics, Inc. - Key Competitors 14
Gamma Therapeutics, Inc. - Key Employees 15
Gamma Therapeutics, Inc. - Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Gamma Therapeutics, Inc., Recent Developments 17
May 01, 2012: Gamma Therapeutics Awarded U.S. Provisional Patent 17
Apr 17, 2012: Gamma Therapeutics to Present GammaCoeur CVD Risk Assay 17
Jul 07, 2011: Gamma Therapeutics's Founder Awarded U.S. Patent 18
Apr 19, 2011: Gamma Therapeutics Awarded Phase II Research Grant 19
Feb 01, 2011: GT Appoints Prestigious Board of Science Advisors to Guide Product Development 19
Nov 18, 2010: Gamma Therapeutics Introduces New Cardiovascular Disease Test 20
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Gamma Therapeutics, Inc. Pipeline Products and Clinical Trials Overview 6
Gamma Therapeutics, Inc. Pipeline Products by Equipment Type 6
Gamma Therapeutics, Inc. Pipeline Products by Indication 7
Gamma Therapeutics, Inc., Key Facts 8
Gamma Therapeutics, Inc., Major Products and Services 9
Gamma Therapeutics, Inc. Number of Pipeline Products by Development Stage 10
Gamma Therapeutics, Inc. Pipeline Products Summary by Development Stage 10
GammaMist - Product Status 11
GammaMist - Product Description 11
GammaSeal - Product Status 12
GammaSeal - Product Description 12
GammaTF - Product Status 13
GammaTF - Product Description 13
Gamma Therapeutics, Inc., Key Employees 15

List of Figures
Gamma Therapeutics, Inc. Pipeline Products by Equipment Type 7
Gamma Therapeutics, Inc. Pipeline Products by Development Stage 10

Companies Mentioned
Dominion Diagnostics, LLC
Castle Biosciences Incorporated
Atherotech, Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.